Thursday, April 17, 2014 1:09:00 PM
Galapagos and partner GlaxoSmithKline say their anti-inflammation candidate hit its mark in a mid-stage trial on psoriasis, a stroke of good news for a drug beset by developmental slipups.
The treatment, 2586184, met its primary endpoint of improving psoriasis severity at 12 weeks in a 66-patient Phase IIa study, the partners said, and the two reported no serious adverse events. Glaxo is running the placebo-controlled study on its own, and, under a 2012 deal between the duo, Galapagos is in line for up to $47 million in milestones and a cut of sales if the drug makes its way to market.
That seemed like a shaky proposition after Galapagos revealed in February that its Big Pharma partner had halted a Phase II study of 2586184 in lupus due to lack of effect and put on hold a Phase I/II trial testing the drug in ulcerative colitis. GSK's moves pinned any hopes for the JAK1 inhibitor on the then-pending psoriasis study, and now, in light of the drug's latest success, the U.K. giant said it plans to review the data before deciding whether to press on into Phase III.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM